NR3C1 and COVID-19: The drug dexamethasone, belonging to the glucocorticoid receptor, corticosteroid agonist, and immunosuppressant categories, was the first drug reported to be able to significantly improve the mortality rate of COVID-19 patients in clinical trials7.